Origin and Mechanism of Action
AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 177–191. Unlike full-length hGH, it does not bind to growth hormone receptors that promote insulin-like growth factor-1 production, thereby avoiding unwanted proliferative effects. Instead, AOD-9604 mimics the way natural hGH regulates fat metabolism by stimulating lipolysis—the breakdown of stored triglycerides—and inhibiting lipogenesis, the formation of new fat cells. This targeted action has positioned the peptide as a promising research subject for obesity and metabolic disorders.
Preclinical Evidence for Fat Reduction
Animal studies, primarily in rodent models, have demonstrated that AOD-9604 significantly reduces body fat mass without affecting blood glucose or insulin levels. Research indicates that repeated subcutaneous administration leads to dose-dependent weight loss, particularly in visceral adipose tissue. Notably, the peptide appears to enhance the activity of affordable research peptides hormone-sensitive lipase, an enzyme critical for releasing free fatty acids from fat stores. These findings have fueled interest in AOD-9604 as a potential alternative to more hazardous lipolytic agents, though human trials remain limited.
Safety Profile and Regulatory Status
Early-phase human studies and toxicology reports suggest that AOD-9604 is well tolerated, with mild side effects such as injection site reactions or transient nausea. Unlike growth hormone, it does not cause joint pain, insulin resistance, or organ enlargement. The peptide is classified as a research chemical by major regulatory bodies, including the FDA, and is not approved for human therapeutic use outside controlled trials. However, its favorable safety margin has allowed it to progress into phase II clinical studies for obesity and hyperlipidemia.
Current Research Directions
Beyond fat loss, investigators are exploring AOD-9604’s potential in cartilage repair and osteoarthritis. Preclinical work reveals that the peptide stimulates proteoglycan synthesis in chondrocytes, suggesting a dual role in metabolic and musculoskeletal health. Additionally, researchers are examining synergistic effects with other peptides, such as BPC-157, to enhance tissue regeneration. Despite promising data, most evidence remains preclinical, and further randomized controlled trials are necessary to confirm efficacy and long-term safety.
Key Considerations for Research Use
Laboratories working with AOD-9604 must adhere to strict purity standards, typically ≥98% purity by HPLC, and reconstitute it in bacteriostatic water or sterile saline. Stability studies indicate that lyophilized peptide retains integrity for months when stored at -20°C, while reconstituted solutions degrade faster at room temperature. Researchers should note that dosage protocols vary widely, with animal studies using 10–100 μg per injection, and human trials employing up to 1 mg daily. No long-term carcinogenicity data exist, making chronic administration outside monitored studies inadvisable.